Non-COPD | COPD | p Value | |
---|---|---|---|
Number of patients | 76 324 (94.0) | 4867 (6.0) | |
Prehospital thrombolysis | 946 (1.4) | 34 (0.8) | 0.007 |
Anticoagulant therapy | <0.001 | ||
Heparin | 5413 (7.1) | 198 (4.1) | |
Dalteparin/enoxaparin | 34 266 (44.9) | 2311 (47.5) | |
Fondaparinux | 15 705 (20.6) | 1147 (23.6) | |
GPIIBIIIA-inhibition | <0.001 | ||
Abciximab | 12 342 (16.2) | 434 (8.9) | |
Tirofiban | 1464 (1.9) | 48 (1.0) | |
Eptifibatide | 4078 (5.3) | 145 (3.0) | |
β-blocker | <0.001 | ||
Intravenous | 17 746 (23.3) | 908 (18.7) | |
Oral | 35 500 (46.5) | 2072 (42.6) | |
Coronary angiography | 55 330 (72.5) | 2697 (55.4) | <0.001 |
Indication for angiography | <0.001 | ||
Unstable angina/NSTEMI | 30 015 (54.2) | 1610 (59.9) | |
STEMI | 21 136 (38.2) | 883 (32.9) | |
Other | 4251 (7.6) | 194 (7.2) | |
Angiographic findings | <0.001 | ||
Normal/atheromatosis | 760 (1.7) | 47 (2.4) | |
1-vessel, no left main disease | 20 788 (47.3) | 860 (43.8) | |
2-vessel, no left main disease | 13 038 (29.7) | 575 (29.3) | |
3-vessel, no left main disease | 7534 (17.1) | 367 (18.7) | |
Left main disease | 226 (0.5) | 14 (0.7) | |
PCI | 42 540 (55.7) | 1837 (37.7) | <0.001 |
Stented | 40 662 (53.3) | 1746 (35.9) | <0.001 |
CABG | 2211 (2.9) | 120 (2.5) | 0.081 |
Complications | |||
Prehospital CPR | 1129 (1.6) | 48 (1.2) | 0.040 |
Cardiogenic shock | 1990 (2.7) | 135 (2.8) | 0.717 |
Defibrillated VT/VF | 1903 (2.5) | 110 (2.3) | 0.285 |
Rupture | 107 (0.1) | 6 (0.1) | 0.097 |
Reinfarction during hospital stay | 956 (1.3) | 67 (1.4) | 0.422 |
CPAP usage | 3700 (4.8) | 477 (9.8) | <0.001 |
Bleeding causing surgery/transfusion | 1233 (1.6) | 117 (2.4) | 0.001 |
AV block II/III | 1424 (1.9) | 94 (1.9) | 0.160 |
Permanent pacemaker | 735 (1.0) | 52 (1.1) | 0.344 |
New onset atrial fibrillation | 3462 (4.6) | 249 (5.2) | 0.107 |
Discharged with flutter/fibrillation | 4519 (6.3) | 417 (9.3) | <0.001 |
LVEF at discharge | <0.001 | ||
Normal LVEF ≥50% | 28 988 (53.8) | 1422 (45.0) | |
LVEF 40–49% | 12 338 (22.9) | 770 (24.3) | |
LVEF 30–39% | 7748 (14.4) | 545 (17.2) | |
LVEF <30% | 3809 (7.1) | 342 (10.8) | |
Discharge medications | |||
ACE inhibitor | 42 350 (55.5) | 2460 (50.6) | <0.001 |
Angiotensin II blocker | 8276 (11.1) | 602 (12.6) | 0.001 |
Aspirin | 68 693 (90.1) | 4158 (85.5) | <0.001 |
Other platelet inhibitor | <0.001 | ||
Clopidogrel | 54 439 (71.4) | 3003 (61.8) | |
Prasugrel | 331 (0.4) | 9 (0.2) | |
Other | 341 (0.4) | 23 (0.5) | |
β-blocker | 65 675 (86.1) | 3778 (77.7) | <0.001 |
Statin | 60 387 (79.2) | 3323 (68.4) | <0.001 |
Calcium channel blocker | 9530 (12.5) | 735 (15.1) | <0.001 |
Digoxin | 2309 (3.0) | 294 (6.0) | <0.001 |
Diuretic | 22 910 (30.0) | 2397 (49.3) | <0.001 |
Nitrate | 9736 (12.8) | 878 (18.1) | <0.001 |
Warfarin | 4039 (5.3) | 314 (6.5) | 0.008 |
The count and percentage are presented for all categorical variables.
AV, atrioventricular; CABG, coronary arterial bypass graft surgery; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia.